Atlas Trials

SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)

Clinical trial NCT02437487 · COMPLETED

Trial details

NCT number
NCT02437487
Sponsor
Seres Therapeutics, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Clostridium Difficile
Start date
2015-05-01
Primary completion
2016-07-01
Enrollment
89

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.